Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. - Wikidata - awgldk - TriplyDB

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

http://www.wikidata.org/entity/Q42963758

about

Progress in treatment of ANCA-associated vasculitis Interventions for renal vasculitis in adults The Prevalence and Management of Pauci-Immune Glomerulonephritis and Vasculitis in Western Countries The Prevalence and Management of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in China Recent advances in understanding and treating vasculitis Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations Hydralazine-induced pauci-immune glomerulonephritis: intriguing case series with misleading diagnoses Therapeutic advances in the treatment of vasculitis Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis Granulomatosis With Polyangiitis in Otolaryngologist Practice: A Review of Current Knowledge Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives Cellular targeting in autoimmunity Nanosized contrast agents to noninvasively detect kidney inflammation by magnetic resonance imaging Understanding the role of B cells in atherosclerosis: potential clinical implications Lupus nephritis: the evolving role of novel therapeutics Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome Current and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Updates in ANCA-associated vasculitis Rituximab in autoimmune diseases What is new in the management of rapidly progressive glomerulonephritis?Pathophysiology of ANCA-associated small vessel vasculitis Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides Genetically distinct subsets within ANCA-associated vasculitis B cells and atherosclerosis.Treatment of renal manifestations of ANCA-associated vasculitis.Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.[Remission induction in ANCA-associated vasculitis: Follow-up data of the RAVE study].Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study.Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.Lung involvement in childhood onset granulomatosis with polyangiitis.Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure.Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.ANCA-associated vasculitis in childhood: recent advances.The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.Clinical features of childhood granulomatosis with polyangiitis (wegener's granulomatosis)Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab.Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case series

P2860

Q21195258-3E8BB81A-AF1C-4B7D-A866-D844AA1BF06C Q24187038-FA84E97E-46AE-4BA9-8519-ABF34A38ADBB Q26740451-181ACF5F-24FD-4EBB-A54B-3EC9B970546A Q26740453-784749D5-59FA-4318-80E9-E52A9A537C95 Q26747046-E0722F8E-340B-4614-9C4C-8A01F6F25A15 Q26748200-1A75F7B9-C66A-487C-9C6A-95BE269079E2 Q26749168-FCD64423-52D0-4342-B294-4FBFC2C9E4BC Q26750499-84EFB3EE-7E75-4BD7-8A40-D7127750CBFA Q26751357-71CDD65C-F848-4629-8586-E12725F8E7F4 Q26765803-D3FE4E01-449A-459D-BA4C-62105DD11B89 Q26775756-E68396A1-0D75-4D9B-98E1-102C4FDA0F7F Q26776308-10ED1933-E2B9-4FB0-AFE6-D32E65D586B5 Q26824580-FA1D8C08-C1E7-4BEA-8F33-EDE20B381545 Q26864381-AC6C7B38-2560-4818-953E-A0059DA95E93 Q26991813-E9EA6064-0686-48E5-99D5-6A7E3F0C4A17 Q26998390-32F4B36C-15EC-4C49-9998-8CBE491E0683 Q27008053-80123F28-C65E-4F98-8739-8CC1C5BC8243 Q27021256-676D815B-1514-4AA9-B096-5435425E6B32 Q27025692-59EC7D39-1723-45EE-8363-4849530BBE28 Q28069897-A05DB141-AD68-4E5F-84AF-A9997A2ED6EA Q28076091-329C0048-8BF9-43DD-96A0-9EE485A30EB0 Q28259540-88124573-2CE0-4FE9-951D-AA40D98D915A Q28383761-094121CC-A85D-4623-927F-3DE62EE5254C Q28393792-8E39B29F-1BFF-487F-A7A2-C418F00817B0 Q28943363-8ABE7D9C-267C-40FC-9E57-11BBB768CE1B Q30252928-FB3E9664-F5F2-4118-9294-734B4AD09A15 Q30486655-B05524B4-9F44-4E1C-A95F-B30040792B91 Q30696868-2BF0DB7F-1BDF-4108-94A2-85C23300D26B Q30704972-3B84CC5A-C421-4215-B241-F1D1198B847D Q30849537-4517B620-2CFC-4281-92D5-9FDB37CB5D52 Q33395310-D8AD0372-0D88-468E-A16E-447FA42A6DE5 Q33418352-CE77283B-39BF-414E-A3F3-7F8373C94BA3 Q33564565-C19D8681-7D77-4B28-A090-C1F3423AC720 Q33571802-B6A025DF-2577-4166-A4B9-055C81A9EEFC Q33620537-FB92593F-B2C0-4BB5-9DA0-698D893E2991 Q33644574-2DC069E4-E280-47FA-8920-236045FEFC76 Q33683956-D9866EEF-E152-4F07-98F0-1746CD15AED7 Q33696589-612F6F9B-7744-4664-8932-308A4BC4DBD0 Q33757203-89817D50-49B6-4191-BBC8-21ACBD3B2CE6 Q33757209-FC1DC8DB-5E7B-42A0-9D69-894E0F9D20D5

P2860

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

http://www.wikidata.org/entity/Q42963758

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

@en

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

@nl

type

label

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

@en

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

@nl

prefLabel

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

@en

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

@nl

P1433

Q42963758-F3E34D5D-3992-40B9-B14A-112E08E7BB7A

P1476

Q42963758-25FC79B2-1D1E-4CD5-9D6E-33039A35B6E7

P2093

Q42963758-1A79D826-AC33-4547-A9F3-44EDD2A2D956

Q42963758-2954A39B-7420-48DF-B081-7BB2DF677ACE

Q42963758-2C6E64C4-E8B3-486C-9D2D-02EBE56870A2

Q42963758-2D9B5062-324A-4BE8-8D6A-FD0F3EC208BC

Q42963758-484348C3-2565-4426-A076-B3C8E916A0FE

Q42963758-4A733D5E-63FC-4CB7-9ED1-BCBA79852920

Q42963758-72995DBB-2077-4AAE-83F3-778F9C687419

Q42963758-7E2EAD00-1959-468A-B49F-DA09D4817B04

Q42963758-832D1984-9F36-4519-8DF6-56B88C390C71

Q42963758-84950AD0-3149-49D7-94EC-661938B1ABE8

P304

Q42963758-4E8328AA-CE36-489D-96B5-4A0F959A8A08

P31

Q42963758-D8C20370-A871-480E-865E-A278BB1D5C37

P356

Q42963758-AD391F73-C2F7-44F4-8C25-7EE00D30B757

P407

Q42963758-47498B51-5143-4A8F-AB2E-F2004E72BF6F

P433

Q42963758-D0CB6FB1-A149-4AE3-9A35-1460FFB2624F

P478

Q42963758-33AA69BA-2250-4CB8-A810-76B3195C0B4C

P50

Q42963758-0A81AB60-43A8-47C4-A297-BC9382459B6C

Q42963758-8DA5B269-8BF4-4429-9313-1FA05CA98B97

Q42963758-8FDB6785-978E-4229-8E00-A67DADD3FA34

P577

Q42963758-0E7FC95D-4AC3-4507-8B4E-9037D4FC3FA4

P698

Q42963758-C7614BEB-6192-47B6-A26B-FF392C7D6A73

P356

P1433

The New England Journal of Medicine

P1476

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

@en

P2093

Caroline O Savage

http://www.w3.org/2001/XMLSchema#string

Chen Au Peh

http://www.w3.org/2001/XMLSchema#string

David R W Jayne

http://www.w3.org/2001/XMLSchema#string

Dorothy Walsh

http://www.w3.org/2001/XMLSchema#string

European Vasculitis Study Group

http://www.w3.org/2001/XMLSchema#string

Kerstin Westman

http://www.w3.org/2001/XMLSchema#string

Matthew D Morgan

http://www.w3.org/2001/XMLSchema#string

Michael Walsh

http://www.w3.org/2001/XMLSchema#string

Mårten Segelmark

http://www.w3.org/2001/XMLSchema#string

Pieter van Paassen

http://www.w3.org/2001/XMLSchema#string

P304

211-220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0909169

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

363

http://www.w3.org/2001/XMLSchema#string

P50

Raashid Ahmed Luqmani

Jan Willem Cohen Tervaert

Vladimír Tesař

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20647198

http://www.w3.org/2001/XMLSchema#string